anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Beta-alanine is a nutritional supplement often consumed by people involved in high-intensity sports that involve substantial lactic acidosis. If consumed on a regular basis, it improves muscle buffering capacity and exercise performance during high-intensity moderate-duration events. CrossFit involves competitions that are high in intensity and moderate duration and many elite CrossFit athletes have reported taking beta-alanine as a supplement. It has never however been evaluated in a research study for its affect on CrossFit performance. The purpose of the study is therefore to assess the effects of beta-alanine supplementation on CrossFit performance. A maximum of 30 CrossFit participants will participate in this randomized double-blind parallel groups study. Participants will be randomized to receive 6.4 g/d beta-alanine or maltodextrin placebo for 3 weeks. At baseline and after the intervention, participants will complete a "Fran" test, which involves performing sets of repeated dumbbell thrusters alternating with chin-ups. The performance measure is the time to complete the test. During the test, respiratory exchange ratio will be assessed to indirectly assess acidosis.
OBJECTIVES: Thoracic endovascular aortic repair (TEVAR) is the preferred treatment for severe blunt thoracic aortic injuries (BTAI). Successful outcomes rely on accurate endograft sizing, but initial imaging may underestimate aortic diameters. This study examines the impact of intravascular ultrasound (IVUS) on endograft sizing and clinical outcomes in BTAI patients.
METHODS: A prospectively collected multi-institutional dataset from the Aortic Trauma Foundation was analyzed. Patients with BTAI undergoing TEVAR with IVUS were compared to patients who underwent TEVAR alone. Demographics and operative variables were compared, focusing on IVUS effects on endograft sizing by examining maximal proximal and distal aortic diameter on initial CT imaging compared to the graft diameters used during TEVAR.
RESULTS: 293 patients underwent TEVAR for BTAI with IVUS utilized in 124 cases (42.3%). The average graft size in the IVUS and non-IVUS groups were similar proximally (26.91 ± 4.3 mm IVUS vs 27.77 ± 4.7 mm non-IVUS, P = 0.116) and distally (25.96 ± 4.7 mm IVUS vs 26.51 ± 4.7 mm non-IVUS). IVUS did not impact the difference between graft size and initial CT measurements proximally (4.32 ± 4.8 mm IVUS vs 4.23 ± 3.9 mm non-IVUS, P = 0.859) or distally (4.17 ± 5.9 mm IVUS vs 4.50 ± 4.3 mm non-IVUS, P = 0.606). Although delayed hemorrhagic and ischemic stroke occurred less frequently in IVUS patients (0.8% IVUS vs 7.1% non- IVUS, P = 0.024), in-hospital mortality was similar between groups (5.6% IVUS vs 7.7% non-IVUS, P = 0.581).
CONCLUSIONS: IVUS is not associated with significant changes in endograft sizing compared to sizing based on CT scan alone in BTAI patients. IVUS was not associated with differences in mortality but was associated with a decrease in delayed hemorrhagic and ischemic stroke. Routine IVUS in BTAI patients may not be necessary for accurate sizing, but there may be a relationship between IVUS and stroke.
The recommended dose is 1 mg (0.2 mL or 20 unit mark) administered as a single daily subcutaneous injection. As with other drugs administered chronically by subcutaneous injection, the injection site should be varied periodically. Each 0.2 mL contains 1 mg of leuprolide acetate, sodium chloride for tonicity adjustment, 1.8 mg of benzyl alcohol as preservative and water for injection. The pH may have been adjusted with sodium hydroxide and/or acetic acid.

Follow the pictorial directions on the reverse side of this package insert for administration.

NOTE: As with all parenteral products, inspect the solution for discoloration and particulate matter before each use.
Previously, cystic fibrosis related diabetes (CFRD) was considered to be a consequence of damage to the pancreas therefore the cells contained in the pancreas--i.e.--islets that house beta cells, which make and release insulin (similar to T1D). Recent evidence suggests that other factors may also be associated that are similar to those with T2D. For example, patients with T2D, have decreased secretion of incretins, hormones released by the small intestine in response to nutrients from food which act, among other things, to increase insulin secretion from Beta cells of the pancreas. When patients with T2D are treated with incretin hormones, their pancreatic Beta cells release more insulin (measured as 'second phase insulin secretion'). Currently, we do not know if patients with CFRD have decreased incretin secretion like T2D or if treating CFRD patients with incretin hormones will improve their insulin levels. This study will measure insulin release from the Beta cells from CFRD patients (second phase insulin secretion) that are being given incretin hormones in the veins. This will be compared with insulin release when the same patients are given a placebo (salt containing solution). The patients and the research team will not know what is being given until all the results are collected. The results will provide unbiased evidence if incretins will help improve insulin release in CFRD patients.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely, to oncology, and pertains to methods for combined treatment of locally advanced cardioesophageal cancer. Chemotherapy courses are conducted according to the regimen including the introduction of oxaliplatin 100 mg/m2, leucovorin at a dose of 400 mg/m2by intravenous drop infusion on 1 day, the duration of infusion 2 hours, 5-fluorouracil at a dose of 400 mg/m2by intravenous jet infusion on 1 day. Then at a dose of 2,400 mg/m2intravenously, the duration of infusion 46 hours. The break between the chemotherapy courses is 2 weeks. In the amount of 6 courses and simultaneously with chemotherapy, radiation therapy is conducted in the mode of standard fractionation of a single boost dose equal to 2 Gy, a total boost dose equal to 46 Gy, 5 times a week. Irradiation is conducted with high-energy photons on a linear electron accelerator, conformal irradiation is applied, the duration of the irradiation course, accounting for weekends, is 31 days. Chemotherapy is also conducted in a neoadjuvant mode, wherein oxaliplatin is introduced at a dose of 100 mg/m2. The irradiation zone includes the abdominal segment of the esophagus, the cardiac section of the stomach, lower mediastinal, paraesophageal, perigastric lymph nodes, lymph collectors in the area of the celiac trunk and branches thereof. The duration of the irradiation course, accounting for weekends, is 31 days. 6 weeks after the completion of preoperative radiation therapy, the tumour response is assessed and surgical intervention is performed in the volume of gastrectomy.EFFECT: method improves the results of combined treatment of locally advanced cardioesophageal cancer by means of combined application of radiation and chemotherapy.1 cl, 1 ex
INTRODUCTION: Ischemic heart disease is a leading cause of death worldwide, and its importance is increasing with the aging population. The aim of this study was to evaluate the accuracy of SurvTrace, a survival analysis model using the Transformer-a state-of-the-art deep learning method-for predicting recurrent cardiovascular events and stratifying high-risk patients. The model's performance was compared to that of a conventional scoring system utilizing real-world data from cardiovascular patients.
METHODS: This study consecutively enrolled patients who underwent percutaneous coronary intervention (PCI) at the Department of Cardiovascular Medicine, University of Tokyo Hospital, between 2005 and 2019. Each patient's initial PCI at our hospital was designated as the index procedure, and a composite of major adverse cardiovascular events (MACE) was monitored for up to two years post-index event. Data regarding patient background, clinical presentation, medical history, medications, and perioperative complications were collected to predict MACE. The performance of two models-a conventional scoring system proposed by Wilson et al. and the Transformer-based model SurvTrace-was evaluated using Harrell's c-index, Kaplan-Meier curves, and log-rank tests.
RESULTS: A total of 3938 cases were included in the study, with 394 used as the test dataset and the remaining 3544 used for model training. SurvTrace exhibited a mean c-index of 0.72 (95% confidence intervals (CI): 0.69-0.76), which indicated higher prognostic accuracy compared with the conventional scoring system's 0.64 (95% CI: 0.64-0.64). Moreover, SurvTrace demonstrated superior risk stratification ability, effectively distinguishing between the high-risk group and other risk categories in terms of event occurrence. In contrast, the conventional system only showed a significant difference between the low-risk and high-risk groups.
CONCLUSION: This study based on real-world cardiovascular patient data underscores the potential of the Transformer-based survival analysis model, SurvTrace, for predicting recurrent cardiovascular events and stratifying high-risk patients.
Subjects in the care control group will perform once-a-week stretching exercise intervention. Each session lasts for 75 minutes and covers the major muscle groups.
Increased exposure to opioids around total knee arthroplasty (TKA) can lead to a risk of long-term dependence. We hypothesized that performing simultaneous bilateral total knee arthroplasty (simBTKA) over staged surgery (staged bilateral total knee arthroplasty [stgBTKA]) may decrease the total amount of opiates used. We retrospectively reviewed 29 patients who underwent simBTKAs performed between February 2015 and November 2020 and identified 23 that did not use opioids ≤90 days prior to surgery. These were frequency matched for gender and body mass index to 50 stgBTKAs completed within 6 months who also were opioid-free ≤90 days prior to their first surgery. Using our state's prescription database, we reviewed postsurgery opioid refills and morphine milligram equivalents (MMEs) for the two groups and compared their initial MME prescription at discharge and their total MME consumption 6 months postoperatively. Total MME consumption for the stgBTKA group included all prescriptions following the first and 6 months after the second surgery, whereas for the simBTKA group, total consumption included the 6 months after their two same-day surgeries. The simBTKA group had more MMEs prescribed initially (median = 375) than did the stgBTKA group after second surgery (median = 300; p < 0.007), larger postoperative-refill MMEs in the first 30 days (median = 300) than stgBTKA (median = 0; p = 0.221) and increased total MME consumption 6 months after surgery (median = 675) compared with stgBTKA after second surgery (median = 450; p = 0.077). However, both groups had similar monthly consumptions rates, with medians I MMEs/month of 112 for simBTKA versus 96 for stgBTKA (p = 0.585). Our results suggest there is no significant difference in opioid consumption between simBTKA and stgBTKA. In fact, we found that simBTKA patients received larger opioid amounts in the immediate postoperative period as well as slightly larger amounts at 30 days.
Multisensory awareness of one's own body relies on the integration of signals from various sensory modalities such as vision, touch, and proprioception. But how do blind individuals perceive their bodies without visual cues, and does the brain of a blind person integrate bodily senses differently from a sighted person? To address this question, we aimed to replicate the only two previous studies on this topic, which claimed that blind individuals do not experience the somatic rubber hand illusion, a bodily illusion triggered by the integration of correlated tactile and proprioceptive signals from the two hands. We used a larger sample size than the previous studies and added Bayesian analyses to examine statistical evidence in favor of the lack of an illusion effect. Moreover, we employed tests to investigate whether enhanced tactile acuity and cardiac interoceptive accuracy in blind individuals could also explain the weaker illusion. We tested 36 blind individuals and 36 age- and sex-matched sighted volunteers. The results show that blind individuals do not experience the somatic rubber hand illusion based on questionnaire ratings and behavioral measures that assessed changes in hand position sense toward the location of the rubber hand. This conclusion is supported by Bayesian evidence in favor of the null hypothesis. The findings confirm that blind individuals do not experience the somatic rubber hand illusion, indicating that lack of visual experience leads to permanent changes in multisensory bodily perception. In summary, our study suggests that changes in multisensory integration of tactile and proprioceptive signals may explain why blind individuals are "immune" to the nonvisual version of the rubber hand illusion.
Per- and polyfluoroalkyl substances (PFAS) have been called "forever chemicals" due to their inherent chemical stability. Their potential toxic effects on aquatic animals and health risk assessments have not been fully elucidated. In this study, we investigated the toxic effects of PFASs at environmentally relevant concentrations (200 ng/L) on crucian carp (Carassius auratus). The results showed that PFAS reduced the comfort behaviour of crucian carp and was associated with reduced levels of acetylcholinesterase and dopamine in the brain. PFAS exposure also decreased the activities of total superoxide dismutase, catalase and glutathione peroxidase, while increasing the levels of malondialdehyde. PFAS caused over-expression of the pro-inflammatory cytokines TNF-α, IFN-γ and stress-related genes Caspase-3, HSP-70 in the fish brain. Pathological staining showed that PFAS caused multifocal demyelination and perineural vacuolization in brain, intestinal tissue also showed reduced villus length and focal damage. PFASs altered the composition of the gut microbiota of crucian carp, significantly increasing the abundance of potentially pathogenic bacteria and the potential pathogenicity of the microbiota. It is suggested that PFASs may cause varying degrees of tissue damage by destabilising the gut microbiota. These results provide insights for assessing the toxicity of PFAS contaminants at aquatic environmental concentrations.
PURPOSE:To obtain a sustained release nasal drop controlling release of an active ingredient in a nasal cavity, having raised retention in a nasal cavity of the active ingredient, comprising a vasoconstrictor and an antihistamine agent as active ingredients. CONSTITUTION:This sustained release nasal drop contains a vasoconstrictor (e.g. tetrahydrozoline hydrochloride) and an antihistamine agent (e.g. chlorpheniramine maleate) as active ingredients. The sustained release nasal drop is further mixed with 1-50-wt.% of an oil component, 0.05-5wt.% of a surfactant, water, a pH adjustor and components useful for an ordinary nasal drop and pharmaceutically manufactured into an O/W emulsion having pH 6.5-8.5. The sustained release nasal drop has high effect on nasal diseases such as pollinosis or rhinitis and has sustained release.
In recent years, advances have been made for treating ascites in patients with cirrhosis. Recent studies have indicated that several treatments that have been used for a long time in the management of portal hypertension may have beneficial effects that were not previously identified. Long-term albumin infusion may improve survival in patients with cirrhosis and ascites while beta-blockers may reduce ascites occurrence. Transjugular intrahepatic porto-systemic shunt (TIPS) placement may also improve survival in selected patients in addition to the control with ascites. Low-flow ascites pump insertion can be another option for some patients with intractable ascites. In this review, we summarize the latest data related to the management of ascites occurring in cirrhosis. There are still unanswered questions, such as the optimal use of albumin as a long-term therapy, the place of beta-blockers, and the best timing for TIPS placement to improve the natural history of ascites, as well as the optimal stent diameter to reduce the risk of shunt-related side-effects. These issued should be addressed in future studies.
Increases in serum transaminases have been reported with use of LESCOL XL [see Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. Persistent increases to more than three times the ULN in serum transaminases have occurred in approximately 1.1% of patients receiving fluvastatin in clinical trials. Marked persistent increases of hepatic transaminases have also occurred with fluvastatin. There have been rare post-marketing reports of fatal and non-fatal hepatic failure in patients taking statins, including LESCOL XL. 

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.

Consider liver enzyme testing before LESCOL XL initiation and thereafter, when clinically indicated. LESCOL XL is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue LESCOL XL.
Control participants will only come to a baseline visit and the only tests that will be completed are the EMG Measures (MUNE, CMAP, decomposition EMG) and EIM. There will be no further testing for those participants. This visit will take approximately 30-60 minutes. A total of 40 control participants are being recruited for this study.
Gastric pain has limited treatment options and the mechanisms within the central circuitry remain largely unclear. This study investigates the central circuitry in gastric pain induced by noxious gastric distension (GD) in mice. Here, we identified that the nucleus tractus solitarius (NTS) serves as the first-level center of gastric pain, primarily via the vagus nerve. The prelimbic cortex (PL) is engaged in the perception of gastric pain. The lateral parabrachial nucleus (LPB) and the paraventricular thalamic nucleus (PVT) are crucial regions for synaptic transmission from the NTS to the PL. The glutamatergic tetra-synaptic NTS-LPB-PVT-PL circuitry is necessary and sufficient for the processing of gastric pain. Overall, our finding reveals a glutamatergic tetra-synaptic NTS-LPB-PVT-PL circuitry that transmits gastric nociceptive signaling by the vagus nerve in mice. It provides an insight into the gastric pain ascending pathway and offers potential therapeutic targets for relieving visceral pain.
Postoperative delirium appear approximately 10-70% of patients older than 65 yrs undergoing surgery and it is strongly associated with poor surgical outcome. The clinical characteristics of postoperative delirium are fluctuating attention, visual hallucination, disorganized thought and alter sleep-wake cycles. This is quite similar to core features of α-synuclein-related cognitive disorders such as parkinson's disease dementia and dementia with lewy body. At that point, investigator thought that postoperative delirium is preclinical stage of a-synucleinopathy. In other words, a-synuclein related disorders and postoperative delirium may share an underlying neurochemical change in their pathogenesis.

investigator will recruit age 65 and older patients scheduled to perform spine surgery. The pre-operative evaluation include neurologic exam, baseline cognitive function and a-synucleinopathy related non motor symptoms through Questionnaires.
BACKGROUND AND AIMS: Epicardial adipose tissue (EAT) surrounds the heart and coronary arteries and is important for comprehending the pathogenesis of coronary artery disease (CAD). We aimed to evaluate the expressions of mitochondrial biogenesis- and CAD-related genes and miRNAs in EAT by comparing them to visceral adipose tissue (VAT) in CAD, diabetes, and obesity subgroups.
METHODS: In this study, a total of 93 individuals were recruited, and EAT samples (63 CAD; 30 non-CAD) and VAT samples from 65 individuals (46 CAD; 19 non-CAD) were collected. For further analysis, the study population was divided according to obesity and diabetes status. PRKAA1, PPARGC1A, SIRT1, RELA, TNFA, and miR-155-5p, let-7g-5p, miR-1247-5p, miR-326 expression levels were examined.
RESULTS: PRKAA1 and let-7g-5p were differentially expressed in EAT compared to VAT. TNFA expression was upregulated significantly in both tissues of CAD patients. In EAT, PRKAA1, PPARGC1A, and SIRT1 were downregulated with diabetes. Moreover, PPARGC1A expression is decreased under the condition of obesity in both tissues. EAT expressions of miR-1247-5p and miR-326 were downregulated with obesity, while miR-155-5p is decreased only in the VAT of obese. Also, miRNAs and genes were correlated with biochemical parameters and each other in EAT and VAT (p < 0.050).
CONCLUSIONS: The findings demonstrating distinct let-7g-5p and AMPKα1 mRNA expression between EAT and VAT underscores the importance of tissue-specific regulation in different clinical outcomes. In addition, the differential expressions of investigated genes and miRNAs highlight their responsiveness to obesity, DM, and CAD in adipose tissues.
FIELD: medicine.SUBSTANCE: method includes carrying out drug treatment, diet therapy, physical exercise, balneotherapy. Drug treatment includes intake of an ACE inhibitor or a beta-blocker 30-40 minutes before the first breakfast. 2-2.5 hours after supper methmorphine in a dose of 500-1000 mg/day is taken in. Diet therapy includes fractional feeding with the calorie content of 1200 kilocalories from Monday to Friday. On Saturday the calorie content is reduced to 800-900 kilocalories, and on Sunday - to 600-700 kilocalories. The physical exercise is carried out in the form of walking in a slow tempo, with stops, with the total duration of 90-120 minutes. Balneotherapy is started with carrying out in the morning of a rain fresh water shower. Then, manual superficial massage of the neck zone is carried out. Baths take place in the period from 12 to 17 o'clock. For their carrying out hydrocarbonate-sulfate-sodium mineral water from Belokurikha resort with an increased content of silicic acid and fluorine, and mineralisation of 0.4 g/l is applied. Radon concentration for bath realisation constitutes 3.9-4.6 nCi/dm, water temperature is 36-37°C. The duration of the bath time is five minutes on the first day, on the second day - eight minutes, on the third day - ten minutes, on the fourth day - rest, on the fifth and sixth days - twelve minutes, on the seventh day - fifteen minutes, on the eighth day - rest, on the following three days the baths are being carried out for 15 minutes.EFFECT: method increases remission duration due to an increase of the non-specific resistance of the organism protection factors, normalisation of oxygenation and metabolic processes in tissues.4 cl, 2 tbl, 2 ex
In this embodiment, the apparatus for producing a hydroxyapatite suspension is provided with a container, a first injection device, a second injection device, a pH meter, a control device, and a discharge device. The first injection device injects calcium hydroxide into the vessel. The second injection means injects phosphoric acid into the solution contained in the container. The pH meter measures the pH of the solution in the container. The control means controls at least one of the concentration of calcium hydroxide injected by the first injection means, the concentration of phosphoric acid injected by the second injection means, and the injection speed so that the pH measured by the pH meter is in a specified range. The discharge device discharges the hydroxyapatite suspension concentrated by natural precipitation of the solution in the container to the outside of the container.